G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 27.2 PLN 3.82% Market Closed
Market Cap: 35.9m PLN
Have any thoughts about
Genomed SA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

20.9
Current
26.8
Median
4.3
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
20.9
=
Enterprise Value
31.8m PLN
/
EBITDA
1.5m PLN
All Countries
Close
Market Cap EV/EBITDA
PL
Genomed SA
WSE:GEN
34.6m PLN 20.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 460.8
US
Abbvie Inc
NYSE:ABBV
299.8B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 17.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD 26.3
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -519.6
AU
CSL Ltd
ASX:CSL
137.3B AUD 20.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 17
US
Seagen Inc
F:SGT
39.3B EUR -59.4
NL
argenx SE
XBRU:ARGX
34B EUR -103.9
EBITDA Growth
PL
G
Genomed SA
WSE:GEN
Average EV/EBITDA: 18.2
20.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 460.8 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.6 N/A
AU
CSL Ltd
ASX:CSL
20.7
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -103.9 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More